Anthera Pharmaceuticals Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Anthera |
Anthera Pharmaceuticals Company Z Score Analysis
Anthera Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionIn accordance with the company's disclosures, Anthera Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
All Next | Launch Module |
Anthera Fundamentals
Return On Equity | -5.69 | ||||
Return On Asset | -1.42 | ||||
Current Valuation | (7.47 M) | ||||
Shares Outstanding | 26.18 M | ||||
Number Of Shares Shorted | 2.02 M | ||||
Price To Earning | (0.20) X | ||||
Price To Book | 0.11 X | ||||
Gross Profit | (28.49 M) | ||||
EBITDA | (26.59 M) | ||||
Net Income | (26.87 M) | ||||
Cash And Equivalents | 8.09 M | ||||
Cash Per Share | 0.31 X | ||||
Debt To Equity | 1.61 % | ||||
Current Ratio | 3.30 X | ||||
Book Value Per Share | 0.21 X | ||||
Cash Flow From Operations | (36.9 M) | ||||
Short Ratio | 2.09 X | ||||
Earnings Per Share | (1.76) X | ||||
Price To Earnings To Growth | (0.05) X | ||||
Target Price | 3.0 | ||||
Number Of Employees | 21 | ||||
Beta | -108.04 | ||||
Market Capitalization | 617.83 K | ||||
Total Asset | 3.67 M | ||||
Retained Earnings | (436.8 M) | ||||
Working Capital | 39.39 M | ||||
Current Asset | 47.86 M | ||||
Current Liabilities | 8.47 M | ||||
Net Asset | 3.67 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |